This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn

This study has been completed.
University of Rochester
Information provided by (Responsible Party):
Cornell University Identifier:
First received: November 24, 2009
Last updated: March 19, 2014
Last verified: March 2014
This study aims to determine how maternal Fe status influences placental and neonatal Fe status in pregnant adolescents and to assess the impact of the Fe endowment of birth on functional outcomes as assessed by auditory brainstem responses within 48 h of delivery in neonates born to these adolescents.


Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn

Resource links provided by NLM:

Further study details as provided by Cornell University:

Primary Outcome Measures:
  • Auditory Brainstem Responses (ABR) in Infant [ Time Frame: within 24-48 h of birth ]

Secondary Outcome Measures:
  • Maternal Fe and micronutrient status (folate, B12, Fe, copper and zinc, hemoglobin, hematocrit,transferrin receptor, hepcidin, erythropoietin, ferritin, erythrocyte zinc protoporphyrin/heme ratios and c-reactive protein) [ Time Frame: Delivery ]
  • Neonatal Fe and micronutrient status [ Time Frame: Delivery ]
  • Placental Fe/copper/zinc content and expression of key iron transporters. [ Time Frame: Delivery ]

Biospecimen Retention:   Samples With DNA
At delivery a 15 mL maternal blood sample, 20 ml cord blood sample and the placenta are collected.

Enrollment: 144
Study Start Date: October 2008
Study Completion Date: October 2013
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Pregnant adolescents in Rochester, NY.

Inclusion Criteria:

  • Adolescents (ages 11-18 y) and their newborns will be eligible to participate if the adolescent is carrying a singleton pregnancy, does not have any preexisting medical complications (such as HIV-infection, eating disorders, hemoglobinopathies, malabsorption diseases, steroid use, substance abuse history, or taking medications known to influence iron homeostasis).

Exclusion Criteria:

  • Individuals with pregnancy induced hypertension or elevated diastolic blood pressure (>110) will not be eligible to participate in the study. In addition, adolescents who have been previously treated for lead exposure, or those that have been identified as having elevated blood lead concentrations during childhood, will be excluded from the study.
  • Data from infants that experience perinatal asphyxia, pathologic neonatal hyperbilirubinemia, respiratory disease, antibiotic therapy (aminoglycosides), CNS infection, sepsis, congenital or middle or external ear lesions, craniofacial anomalies, chromosomal disorders, TORCH (toxoplasmosis, other infections, rubella, cytomegalovirus infection and herpes simplex infection) or those that were clinically unstable with the first 48 h post-delivery will be excluded from ABR studies. Infants born to mothers with positive drug abuse screens at delivery will also be excluded from further study (these screens are automatically run among this age group). Infants that are identified with hearing deficits at birth using the OAE screening will be excluded from the ABR measures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01019902

United States, New York
Highland Hospital
Rochester, New York, United States, 14642
Sponsors and Collaborators
Cornell University
University of Rochester
Principal Investigator: Kimberly O'Brien, PhD Cornell University
Principal Investigator: Ronnie Guillet, MD, PhD University of Rochester